Sri Mr. Dilip Shanghvi
was founder and currently as MD of Sun
pharma. Established in 1983 with a portfolio of 5 products, Sun Pharma has
emerged as the world’s fifth largest specialty generic pharmaceutical company
and India’s top pharmaceutical company. It provides high-quality, affordable
medicines trusted by customers and patients across the world. Currently 2000 products in market under Sun
pharma
Core Team:
ISRAEL MAKOV
Chairman
Chairman
SAILESH T. DESAI
Executive Director
Executive Director
DILIP SHANGHVI
Managing Director
Managing Director
SUDHIR V. VALIA
Executive Director
Executive Director
Global presence and Operational Capacity: The
Company’s global presence is supported by 49 manufacturing facilities, spanning
six continents, R&D centres across the globe and a multi-cultural workforce
comprising over 50 nationalities. Sun Pharma have Plants Across the world, with
Total revenue of $ 4.3 Billion. Nearly 30.000 Employees work for Sun Pharma.
35 finished dosage manufacturing sites-India: 15 US: 6 Brazil: 2 One each at
Canada, Ireland, South Africa, Malaysia, Mexico, Hungary, Israel, Bangladesh,
Romania, Morocco, Egypt and Nigeria Delivery formats
14 API manufacturing sites- India: 9 Australia: 2 One each at Israel,
US and Hungary Key API plants The Panoli and Ahmednagar (both in India) has US
FDA and European approvals
Main Milestones
and Key AQuasitions:
- 2015 Acquisition of InSite Vision
- 2015 Acquisition of GSK’s Opiates Business
- 2015 Sun Pharma – Ranbaxy Merger
- 2014 Acquired Pharmalucence
- 2013 Formation of Sun-Intrexon JV
- 2013 Acquired URL’s generic business
- 2012 Acquired DUSA Pharma, Inc
- 2010 Acquired Taro Pharmaceutical Industries Ltd
- 2008 Acquired Chattem Chemicals, Inc
- 1997 Acquired Caraco
